ION Breast Cancer Clinical Pathways - ION Solutions

Neoadjuvant Breast: HER2/neu NegativeHormone Therapy (for hormone receptor positive tumors only):Aromatase InhibitorAnastrozole 1mg PO q D x 5 yearsExemestane 25mg PO q D x 5 yearsLetrozole 2.5mg PO q D x 5 years>> JCO 26:1059-1065, 2008Chemotherapy:Adriamycin (Doxorubicin) Cytoxan (Cyclophosphamide) Followed by Taxotere(Docetaxel) EP=High; FN=10%-20%Doxorubicin 60mg/m2 IVP D1Cyclophosphamide 600mg/m2 D1q 14 or 21 Day Cycle x 4 CyclesFollowed by:Docetaxel 100 mg/m2 D1q 21 Day Cycle x 4 Cycles>> JCO 24: 5381-5387, 2006>> Surgical Clinics of North America 83:943-971, 2003DOSE DENSE Adriamycin (Doxorubicin) Cytoxan (Cyclophosphamide) Followed byDOSE DENSE Taxol (Paclitaxel) EP=High; FN˃20%Doxorubicin 60mg/m2 D1Cyclophosphamide 600mg/m2 D1q 14 Day Cycle x 4 CyclesFollowed by:Paclitaxel 175mg/ m2 D1 (or weekly equivalent)q 14 Day Cycle x 4 Cycles>> J Clin Onc 21: 1431-9, 2003Taxotere (Docetaxel) Cytoxan (Cyclophosphamide) EP=Moderate; FN˃20%Docetaxel 75mg/m 2 D1Cyclophosphamide 600mg/m 2 D1q 21 Day Cycle x 4 Cycles>> San Antonio Breast Cancer Symposium. Abstract 12, 2007Taxotere (Docetaxel) Adriamycin (Doxorubicin) Cytoxan (Cyclophosphamide)EP=High; FN˃20%Docetaxel 75mg/m 2 D1Doxorubicin 50mg/m 2 D1Cyclophosphamide 500mg/m 2 D1q 21 Day Cycle x 6 Cycles>> N Engl J Med 352: 22, 2005Clinical Trial:Screen patient for clinical trial. Check www.clinicaltrials.gov for available trials.Page 2 of 39© 2013 by ION Solutions. All rights reserved